FROM THE ARCHIVE
Major prostate study launched
Facebook
Twitter
Email
WEDNESDAY, JULY 25, 2001 The National Cancer Institute on Tuesday announced a 12-year, multi-country effort of 32,000 healthy men aimed at preventing prostate cancer. The study will focus on whether vitamin E and selenium ward help prevent the disease, which is the second deadliest form of cancer for men in the United States. Canadian men will also be involved in the study. The study will focus on men 55 and older. Interested men can visit the institute's SELECT web site at http://www.crab.org/select. The National Cancer Institute is part of the National Institutes of Health. Get the Story:
U.S. Prostate Cancer Study Stresses Prevention (Reuters 7/25)
Largest-Ever Prostate Cancer Prevention Trial Opens: 32,000 Men Sought to Test Vitamin E and Selenium (NIH 7/24) Relevant Links:
National Cancer Institute - http://www.nci.nih.gov
Advertisement
Stay Connected
Contact
Search
Trending in News
1 White House Council on Native American Affairs meets quick demise under Donald Trump
2 'A process of reconnecting': Young Lakota actor finds ways to stay tied to tribal culture
3 Jenni Monet: Bureau of Indian Affairs officer on leave after fatal shooting of Brandon Laducer
4 'A disgraceful insult': Joe Biden campaign calls out Navajo leader for Republican speech
5 Kaiser Health News: Sisters from Navajo Nation died after helping coronavirus patients
2 'A process of reconnecting': Young Lakota actor finds ways to stay tied to tribal culture
3 Jenni Monet: Bureau of Indian Affairs officer on leave after fatal shooting of Brandon Laducer
4 'A disgraceful insult': Joe Biden campaign calls out Navajo leader for Republican speech
5 Kaiser Health News: Sisters from Navajo Nation died after helping coronavirus patients
News Archive
About This Page
You are enjoying stories from the Indianz.Com Archive, a collection dating back to 2000. Some outgoing links may no longer work due to age.
All stories are available for publishing via Creative Commons License: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)